Berna C Ã-zdemir

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5927131/publications.pdf

Version: 2024-02-01

20 papers

2,946 citations

759233 12 h-index 794594 19 g-index

22 all docs 22 docs citations

times ranked

22

6284 citing authors

#	Article	IF	CITATIONS
1	Depletion of Carcinoma-Associated Fibroblasts and Fibrosis Induces Immunosuppression and Accelerates Pancreas Cancer with Reduced Survival. Cancer Cell, 2014, 25, 719-734.	16.8	1,892
2	TGF-β1–Containing Exosomes from Injured Epithelial Cells Activate Fibroblasts to Initiate Tissue Regenerative Responses and Fibrosis. Journal of the American Society of Nephrology: JASN, 2013, 24, 385-392.	6.1	340
3	Racial Differences in Cancer Susceptibility and Survival: More Than the Color of the Skin?. Trends in Cancer, 2017, 3, 181-197.	7.4	116
4	Sex Differences in Efficacy and Toxicity of Systemic Treatments: An Undervalued Issue in the Era of Precision Oncology. Journal of Clinical Oncology, 2018, 36, 2680-2683.	1.6	100
5	Sex Hormones and Anticancer Immunity. Clinical Cancer Research, 2019, 25, 4603-4610.	7.0	82
6	The Molecular Signature of the Stroma Response in Prostate Cancer-Induced Osteoblastic Bone Metastasis Highlights Expansion of Hematopoietic and Prostate Epithelial Stem Cell Niches. PLoS ONE, 2014, 9, e114530.	2.5	42
7	Androgen receptor functions as transcriptional repressor of cancer-associated fibroblast activation. Journal of Clinical Investigation, 2018, 128, 5531-5548.	8.2	40
8	The challenges of modeling hormone receptor-positive breast cancer in mice. Endocrine-Related Cancer, 2018, 25, R319-R330.	3.1	33
9	Sustained androgen receptor signaling is a determinant of melanoma cell growth potential and tumorigenesis. Journal of Experimental Medicine, 2021, 218, .	8.5	31
10	Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors. Cancer Treatment Reviews, 2021, 100, 102282.	7.7	25
11	Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology., 2021, 9, e002220.		22
12	Sex and Gender Differences in Anticancer Treatment Toxicity: A Call for Revisiting Drug Dosing in Oncology. Endocrinology, 2022, 163, .	2.8	21
13	Current and Future Applications of Novel Immunotherapies in Urological Oncology: A Critical Review of the Literature. European Urology Focus, 2018, 4, 442-454.	3.1	10
14	Deep Response to Anti-PD-1 Therapy of Metastatic Neurofibromatosis Type 1-Associated Malignant Peripheral Nerve Sheath Tumor With <i>CD274/PD-L1</i> Amplification. JCO Precision Oncology, 2019, 3, 1-6.	3.0	10
15	Acute cardiac manifestations under immune checkpoint inhibitors—beware of the obvious: a case report. European Heart Journal - Case Reports, 2021, 5, ytab262.	0.6	6
16	Human epidermal growth factor receptor 2-positive digestive tumors. Current Opinion in Oncology, 2019, 31, 354-361.	2.4	4
17	Prescription Patterns, Recurrence, and Toxicity Rates of Adjuvant Treatment for Stage III/IV Melanoma—A Real World Single-Center Analysis. Biology, 2022, 11, 422.	2.8	4
18	Long-lasting, irreversible and late-onset immune-related adverse events (irAEs) from immune checkpoint inhibitors (ICIs): A real-world data analysis Journal of Clinical Oncology, 2020, 38, e15095-e15095.	1.6	3

#	Article	IF	CITATIONS
19	Androgen Signaling in the Tumor Microenvironment. Advances in Experimental Medicine and Biology, 2021, 1270, 169-183.	1.6	1
20	Personalized treatment of immune checkpoint inhibitor-related severe hemophagocytic lymphohistiocytosis (HLH) Journal of Clinical Oncology, 2020, 38, e15079-e15079.	1.6	0